UPDATE: BioMimetic Therapeutics (BMTI) trading halted for info
Tweet
Share
E-mailGet Alerts BMTI Hot Sheet
Join SI Premium – FREE
(Updated - March 1, 2013 8:56 AM EST)
BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) trading halted for information.
UPDATE - On February 5, 2013, BioMetric disclosed that it received an informal request for clarification from the U.S. Food and Drug Administration (FDA) consisting of six questions, some with multiple subparts, related to the Augment Bone Graft Pre-Market Approval (PMA) review. The company said it submitted a response at that time.
The halt may have something to do with that disclosure, though this would be just speculation on our part. Shares closed up 0.6 percent to $9.49 on Thursday.
BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) trading halted for information.
UPDATE - On February 5, 2013, BioMetric disclosed that it received an informal request for clarification from the U.S. Food and Drug Administration (FDA) consisting of six questions, some with multiple subparts, related to the Augment Bone Graft Pre-Market Approval (PMA) review. The company said it submitted a response at that time.
The halt may have something to do with that disclosure, though this would be just speculation on our part. Shares closed up 0.6 percent to $9.49 on Thursday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Novo Nordisk's ziltivekimab fails to reduce heart risk in ZEUS trial
- Parsons Corporation (PSN) halted on volatility, down 33%
- Outlook Therapeutics (OTLK) halted, news pending
Create E-mail Alert Related Categories
FDA, Insiders' Blog, Trading HaltsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
